Index RUT
P/E -
EPS (ttm) -1.20
Insider Own 34.84%
Shs Outstand 21.38M
Perf Week 4.33%
Market Cap 153.81M
Forward P/E -
EPS next Y -4.08
Insider Trans 0.12%
Shs Float 20.79M
Perf Month 22.96%
Income -27.92M
PEG -
EPS next Q -0.33
Inst Own 59.15%
Short Float 10.59%
Perf Quarter -33.06%
Sales 2.00M
P/S 76.90
EPS this Y 35.34%
Inst Trans -
Short Ratio 3.11
Perf Half Y 30.98%
Book/sh 5.95
P/B 0.81
EPS next Y -137.09%
ROA -25.18%
Short Interest 2.20M
Perf Year -
Cash/sh 6.07
P/C 0.79
EPS next 5Y -
ROE -26.35%
52W Range 2.13 - 20.71
Perf YTD -11.07%
Dividend Est. -
P/FCF -
EPS past 5Y -16.23%
ROI -14.69%
52W High -76.73%
Beta -
Dividend TTM -
Quick Ratio 43.12
Sales past 5Y 0.00%
Gross Margin 96.55%
52W Low 126.29%
ATR (14) 0.40
Dividend Ex-Date -
Current Ratio 43.12
EPS Y/Y TTM -
Oper. Margin -1637.15%
RSI (14) 54.14
Volatility 9.74% 8.63%
Employees 10
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -1395.90%
Recom 1.00
Target Price 39.20
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q 25.92%
Payout -
Rel Volume 0.45
Prev Close 4.70
Sales Surprise -
EPS Surprise 40.52%
Sales Q/Q -
Earnings May 15 BMO
Avg Volume 707.43K
Price 4.82
SMA20 8.25%
SMA50 4.38%
SMA200 -29.10%
Trades
Volume 319,080
Change 2.55%
Date
Action
Analyst
Rating Change
Price Target Change
May-02-24 Initiated
H.C. Wainwright
Buy
$32
Mar-25-24 Initiated
Leerink Partners
Outperform
$26
Aug-08-23 Initiated
TD Cowen
Outperform
Aug-08-23 Initiated
Piper Sandler
Overweight
$67
Aug-08-23 Initiated
JMP Securities
Mkt Outperform
$30
Aug-08-23 Initiated
Goldman
Buy
$33
May-16-24 08:00AM
May-15-24 12:53PM
08:00AM
May-07-24 08:00AM
May-06-24 08:00AM
08:00AM
Loading…
Apr-22-24 08:00AM
Mar-27-24 04:01PM
Mar-25-24 07:00AM
06:15AM
Feb-29-24 08:00AM
Jan-25-24 08:58PM
Jan-23-24 05:45PM
Jan-22-24 11:10PM
07:00AM
Dec-04-23 08:00AM
08:00AM
Loading…
Nov-28-23 08:00AM
Nov-22-23 08:00AM
Nov-13-23 08:00AM
Nov-10-23 08:30AM
Oct-24-23 11:00AM
Oct-18-23 04:05PM
Sep-27-23 04:05PM
Aug-29-23 10:21AM
Aug-21-23 04:02PM
Aug-15-23 04:04PM
Aug-08-23 10:02AM
Jul-20-23 04:05PM
Jul-13-23 09:10PM
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Happel David President & CEO Mar 26 '24 Buy 5.27 12,100 63,731 639,200 Mar 28 04:08 PM Happel David President & CEO Dec 07 '23 Buy 4.10 1,600 6,560 627,100 Dec 08 04:05 PM Happel David President & CEO Nov 16 '23 Buy 2.35 590 1,386 590 Nov 20 09:59 PM Kemble George Executive Chairman Sep 07 '23 Option Exercise 0.79 5,630 4,448 5,630 Sep 08 04:15 PM SEIDENBERG BETH C Director Jul 18 '23 Buy 16.00 46,875 750,000 46,875 Jul 20 04:20 PM NEW ENTERPRISE ASSOCIATES 13 L 10% Owner Jul 18 '23 Buy 16.00 30,000 480,000 3,850,275 Jul 20 06:56 PM NEW ENTERPRISE ASSOCIATES 13 L 10% Owner Jul 18 '23 Sale 16.00 662 10,592 3,820,275 Jul 20 06:56 PM
Index RUT
P/E -
EPS (ttm) -2.46
Insider Own 36.58%
Shs Outstand 97.87M
Perf Week -5.92%
Market Cap 408.99M
Forward P/E -
EPS next Y -4.15
Insider Trans -0.10%
Shs Float 62.80M
Perf Month -2.59%
Income -240.16M
PEG -
EPS next Q -0.79
Inst Own 75.69%
Short Float 13.58%
Perf Quarter -49.39%
Sales 0.00M
P/S -
EPS this Y 39.93%
Inst Trans -
Short Ratio 7.24
Perf Half Y -51.35%
Book/sh 6.52
P/B 0.63
EPS next Y -27.35%
ROA -48.23%
Short Interest 8.53M
Perf Year -80.22%
Cash/sh 6.85
P/C 0.60
EPS next 5Y -
ROE -53.53%
52W Range 4.14 - 29.88
Perf YTD -44.64%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -37.22%
52W High -86.18%
Beta 2.55
Dividend TTM -
Quick Ratio 13.27
Sales past 5Y 0.00%
Gross Margin -
52W Low -0.24%
ATR (14) 0.33
Dividend Ex-Date -
Current Ratio 13.27
EPS Y/Y TTM -
Oper. Margin 0.00%
RSI (14) 32.59
Volatility 7.31% 6.44%
Employees 130
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.40
Target Price 28.50
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 80.32%
Payout -
Rel Volume 0.48
Prev Close 4.22
Sales Surprise -
EPS Surprise 62.96%
Sales Q/Q -
Earnings May 14 AMC
Avg Volume 1.18M
Price 4.13
SMA20 -7.61%
SMA50 -25.05%
SMA200 -57.60%
Trades
Volume 562,220
Change -2.13%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-13-23 Initiated
Wells Fargo
Equal Weight
$11
Dec-08-23 Initiated
Citigroup
Neutral
$8
Sep-13-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$19
Sep-05-23 Initiated
H.C. Wainwright
Buy
$44
May-30-23 Initiated
TD Cowen
Outperform
May-30-23 Initiated
Piper Sandler
Overweight
$68
May-30-23 Initiated
Morgan Stanley
Overweight
May-30-23 Initiated
Jefferies
Buy
$31
May-15-24 11:54AM
May-09-24 08:01AM
08:00AM
Apr-29-24 04:05PM
Mar-28-24 10:53PM
04:05PM
Loading…
04:05PM
Mar-27-24 04:01PM
Mar-21-24 11:12AM
Mar-20-24 07:00AM
12:39AM
Mar-11-24 10:04AM
(FierceBiotech.com) +10.96%
08:02AM
08:00AM
Feb-15-24 04:05PM
Jan-10-24 11:30AM
09:56AM
Loading…
Jan-04-24 09:56AM
Jan-01-24 09:35AM
Dec-27-23 10:45AM
Dec-20-23 04:30PM
Dec-19-23 12:13AM
Dec-18-23 04:14PM
Dec-12-23 09:25PM
Dec-11-23 09:35AM
Dec-04-23 03:00PM
08:00AM
Nov-30-23 04:30PM
Nov-28-23 05:55PM
01:44PM
07:24AM
Nov-27-23 09:09PM
04:30PM
Loading…
04:30PM
Nov-20-23 11:01AM
Nov-16-23 06:42PM
04:11PM
Nov-07-23 05:11PM
04:05PM
Nov-06-23 07:00AM
Oct-31-23 04:30PM
Oct-18-23 09:00PM
Oct-03-23 07:00AM
Sep-15-23 05:39PM
Sep-11-23 04:05PM
Sep-06-23 07:00AM
Aug-15-23 07:22PM
Aug-14-23 04:05PM
Aug-07-23 04:30PM
Jul-18-23 07:00AM
Jun-15-23 04:05PM
May-09-23 04:10PM
May-05-23 07:08PM
(The Wall Street Journal)
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Lin Shao-Lee Chief Executive Officer Apr 01 '24 Sale 6.63 9,961 66,024 1,577,374 Apr 03 06:18 PM Lin Shao-Lee Chief Executive Officer Feb 20 '24 Sale 7.60 15,701 119,403 1,587,335 Feb 22 07:04 PM Lin Shao-Lee Chief Executive Officer Jan 02 '24 Sale 7.41 10,691 79,188 1,603,036 Jan 04 06:09 PM
Index RUT
P/E -
EPS (ttm) -2.04
Insider Own 22.19%
Shs Outstand 44.45M
Perf Week -10.34%
Market Cap 1.99B
Forward P/E -
EPS next Y -2.39
Insider Trans -13.61%
Shs Float 41.79M
Perf Month -4.08%
Income -94.30M
PEG -
EPS next Q -0.55
Inst Own 90.24%
Short Float 16.28%
Perf Quarter -19.94%
Sales 0.00M
P/S -
EPS this Y 0.39%
Inst Trans 1.76%
Short Ratio 7.11
Perf Half Y 181.99%
Book/sh 6.49
P/B 5.72
EPS next Y -6.48%
ROA -29.99%
Short Interest 6.80M
Perf Year 392.83%
Cash/sh 7.52
P/C 4.94
EPS next 5Y -
ROE -36.89%
52W Range 7.10 - 50.78
Perf YTD 141.29%
Dividend Est. -
P/FCF -
EPS past 5Y 10.22%
ROI -23.31%
52W High -26.92%
Beta 1.03
Dividend TTM -
Quick Ratio 28.05
Sales past 5Y 0.00%
Gross Margin -
52W Low 422.68%
ATR (14) 2.72
Dividend Ex-Date -
Current Ratio 28.05
EPS Y/Y TTM 40.28%
Oper. Margin 0.00%
RSI (14) 37.10
Volatility 6.92% 6.49%
Employees 51
Debt/Eq 0.15
Sales Y/Y TTM -
Profit Margin -
Recom 1.22
Target Price 60.22
Option/Short Yes / Yes
LT Debt/Eq 0.14
EPS Q/Q 30.25%
Payout -
Rel Volume 0.83
Prev Close 37.08
Sales Surprise -
EPS Surprise -5.58%
Sales Q/Q -
Earnings May 09 BMO
Avg Volume 957.53K
Price 37.11
SMA20 -10.83%
SMA50 -10.77%
SMA200 42.13%
Trades
Volume 797,006
Change 0.08%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-25-24 Initiated
Oppenheimer
Outperform
$26
Jan-08-24 Initiated
Cantor Fitzgerald
Overweight
Dec-18-23 Initiated
Raymond James
Outperform
$29
Nov-10-23 Upgrade
Jefferies
Hold → Buy
$18 → $26
Aug-16-23 Initiated
Guggenheim
Buy
$27
Jan-04-23 Downgrade
Wedbush
Outperform → Neutral
$33 → $8
Jan-04-23 Downgrade
Jefferies
Buy → Hold
$32 → $6
Jul-12-22 Initiated
JP Morgan
Overweight
$35
May-02-22 Initiated
H.C. Wainwright
Buy
$35
Apr-19-22 Initiated
Wedbush
Outperform
$32
May-17-24 04:27PM
May-10-24 05:38AM
May-09-24 01:53PM
08:00AM
May-07-24 04:38PM
05:09PM
Loading…
Apr-23-24 05:09PM
(The Wall Street Journal)
Apr-13-24 05:29AM
Apr-12-24 07:01PM
Apr-11-24 04:29PM
(Yahoo Finance Video) +17.30%
Apr-05-24 06:30PM
Apr-02-24 08:00AM
Mar-20-24 12:52PM
07:30AM
Feb-28-24 04:20PM
Feb-02-24 12:40PM
08:00AM
Loading…
08:00AM
Feb-01-24 04:05PM
Jan-29-24 11:50PM
06:15AM
Jan-25-24 06:30AM
Jan-12-24 06:44PM
Jan-08-24 08:01AM
08:00AM
Dec-27-23 08:00AM
Dec-15-23 10:15AM
Nov-14-23 05:05PM
09:55AM
Nov-09-23 09:29AM
08:00AM
Nov-04-23 10:00AM
08:00AM
Loading…
Oct-30-23 08:00AM
Oct-18-23 09:35AM
Oct-17-23 09:35AM
Oct-16-23 09:35AM
Oct-13-23 10:22AM
Sep-26-23 04:02PM
Aug-31-23 08:00AM
Aug-16-23 10:00AM
Aug-15-23 04:03PM
Aug-10-23 08:00AM
Aug-04-23 06:30PM
Jul-24-23 09:01AM
Jul-07-23 06:35PM
Jun-27-23 08:05AM
Jun-20-23 07:04PM
09:33AM
Jun-17-23 10:10AM
Jun-15-23 04:44PM
Jun-12-23 12:05PM
Jun-11-23 01:08PM
Jun-08-23 08:00AM
Jun-07-23 08:00AM
May-11-23 08:36AM
07:30AM
May-04-23 08:00AM
Mar-28-23 07:30AM
Feb-27-23 04:05PM
Feb-14-23 07:48AM
Feb-09-23 06:51AM
05:54AM
Feb-06-23 04:05PM
Feb-01-23 09:52PM
04:01PM
Jan-30-23 07:35AM
06:00AM
Jan-25-23 08:00AM
Jan-22-23 07:39AM
Jan-06-23 05:02AM
Jan-04-23 04:07PM
(Investor's Business Daily) -64.70%
12:20PM
10:22AM
06:52AM
Jan-03-23 04:01PM
Dec-20-22 04:05PM
Nov-25-22 07:38AM
Nov-22-22 07:30AM
Nov-17-22 07:30AM
Nov-09-22 07:30AM
Nov-05-22 04:50PM
Oct-17-22 07:30AM
Sep-15-22 09:55AM
Sep-07-22 07:30AM
Aug-29-22 09:55AM
Aug-12-22 09:55AM
Aug-10-22 07:30AM
Aug-04-22 07:30AM
Jul-06-22 07:30AM
Jun-18-22 08:20AM
Jun-04-22 02:30PM
Jun-02-22 07:30AM
May-20-22 04:05PM
May-16-22 07:30AM
May-05-22 04:05PM
May-03-22 04:33PM
May-02-22 07:06PM
Apr-12-22 07:30AM
Mar-24-22 06:30AM
Mar-21-22 07:30AM
Mar-17-22 07:30AM
Mar-01-22 07:30AM
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 16 '24 Option Exercise 7.87 20,651 162,523 69,357 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 16 '24 Sale 42.32 20,651 873,890 51,206 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 15 '24 Option Exercise 3.94 8,221 32,387 61,392 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 15 '24 Sale 42.27 10,186 430,546 51,206 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR Apr 10 '24 Sale 40.00 5,714 228,560 53,171 Apr 12 04:02 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Option Exercise 14.87 99,828 1,484,442 166,165 Apr 05 09:32 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Sale 39.61 99,828 3,954,516 66,337 Apr 05 09:32 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Sale 39.42 18,649 735,205 0 Apr 05 09:32 PM Katabi Maha Director Mar 25 '24 Sale 40.50 340,000 13,770,000 2,793,987 Mar 25 09:46 PM Katabi Maha Director Mar 22 '24 Sale 40.51 413,450 16,748,860 3,133,987 Mar 25 09:46 PM Katabi Maha Director Mar 21 '24 Sale 44.20 81,009 3,580,723 3,547,437 Mar 25 09:46 PM Katabi Maha Director Jan 30 '24 Buy 31.00 161,290 4,999,990 3,628,446 Feb 01 05:58 PM COMMODORE CAPITAL LP 10% Owner Jan 10 '24 Sale 18.00 1,050,000 18,900,000 4,400,000 Jan 12 09:55 PM Fordyce Marshall President and CEO Dec 29 '23 Option Exercise 2.87 13,516 38,854 256,877 Jan 03 04:15 PM Fordyce Marshall President and CEO Aug 21 '23 Sale 16.66 5,210 86,779 243,361 Aug 23 05:56 PM Curley Joanne Chief Development Officer Aug 21 '23 Sale 16.66 1,490 24,817 26,962 Aug 23 05:57 PM Lin Celia Chief Medical Officer Aug 21 '23 Sale 16.65 1,490 24,816 11,010 Aug 23 05:59 PM Young Joseph R SVP, Finance, Chief Acct Offcr Jul 05 '23 Option Exercise 3.94 10,000 39,396 32,679 Jul 06 04:05 PM Grant Sean Chief Financial Officer Jun 23 '23 Buy 16.60 5,000 83,000 5,992 Jun 23 04:05 PM COMMODORE CAPITAL LP 10% Owner Jun 20 '23 Buy 15.17 448,217 6,799,004 5,450,000 Jun 22 04:10 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite